A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

This Phase II/III trial is testing a four-drug combination — surufatinib (a targeted anti-tumor drug), camrelizumab (immunotherapy), nab-paclitaxel (chemotherapy), and gemcitabine (chemotherapy) — as a first-line treatment for metastatic pancreatic cancer, which is one of the hardest cancers to treat. **You may be eligible if...** - You are 18–75 years old - You have pancreatic cancer confirmed by biopsy and it has spread to other organs (Stage IV / metastatic) - You have not yet received any treatment for your metastatic pancreatic cancer - You have at least one measurable lesion - You are in good general health (ECOG 0–1) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have received anti-tumor therapy within the past 2 weeks - You have another active cancer in the past 5 years - You have had major surgery within the last 60 days - You have active autoimmune disease or are on immunosuppressive medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.